Gene · 6607
Papers3,510
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,981 to 2,000 of 3,510
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Unraveling the Pathways to Neuronal Homeostasis and Disease: Mechanistic Insights into the Role of RNA-Binding Proteins and Associated Factors. | Int J Mol Sci | 2018 | 30081499 | PubTator, text mining | PubMed |
| Molecular Factors Involved in Spinal Muscular Atrophy Pathways as Possible Disease-modifying Candidates. | Curr Genomics | 2018 | 30065610 | PubTator, text mining | PubMed |
| Amyotrophic lateral sclerosis: the complex path to precision medicine. | J Neurol | 2018 | 30054789 | PubTator, text mining | PubMed |
| Alternative splicing in cardiomyopathy. | Biophys Rev | 2018 | 30051286 | PubTator, text mining | PubMed |
| Prospective and longitudinal natural history study of patients with Type 2 and 3 spinal muscular atrophy: Baseline data NatHis-SMA study. | PLoS One | 2018 | 30048507 | PubTator, text mining | PubMed |
| An observational study of functional abilities in infants, children, and adults with type 1 SMA. | Neurology | 2018 | 30045959 | PubTator, text mining | PubMed |
| Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA). | J Med Chem | 2018 | 30044619 | PubTator, text mining | PubMed |
| A Semi-Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy. | CPT Pharmacometrics Syst Pharmacol | 2018 | 30043511 | PubTator, text mining | PubMed |
| Nusinersen: A Review in 5q Spinal Muscular Atrophy. | CNS Drugs | 2018 | 30027400 | PubTator, text mining | PubMed |
| A complex of C9ORF72 and p62 uses arginine methylation to eliminate stress granules by autophagy. | Nat Commun | 2018 | 30022074 | PubTator, text mining | PubMed |
| Dysregulation of Mdm2 and Mdm4 alternative splicing underlies motor neuron death in spinal muscular atrophy. | Genes Dev | 2018 | 30012555 | PubTator, text mining | PubMed |
| Combined deficiency of Senataxin and DNA-PKcs causes DNA damage accumulation and neurodegeneration in spinal muscular atrophy. | Nucleic Acids Res | 2018 | 30010942 | PubTator, text mining | PubMed |
| Impact of missense mutations in survival motor neuron protein (SMN1) leading to Spinal Muscular Atrophy (SMA): A computational approach. | Metab Brain Dis | 2018 | 30006696 | PubTator, text mining | PubMed |
| Two breakthrough gene-targeted treatments for spinal muscular atrophy: challenges remain. | J Clin Invest | 2018 | 29985170 | PubTator, text mining | PubMed |
| Light modulation ameliorates expression of circadian genes and disease progression in spinal muscular atrophy mice. | Hum Mol Genet | 2018 | 29982483 | PubTator, text mining | PubMed |
| Mild SMN missense alleles are only functional in the presence of SMN2 in mammals. | Hum Mol Genet | 2018 | 29982416 | PubTator, text mining | PubMed |
| Vibration-Assisted Home Training Program for Children With Spinal Muscular Atrophy. | Child Neurol Open | 2018 | 29977975 | PubTator, text mining | PubMed |
| Principles for targeting RNA with drug-like small molecules. | Nat Rev Drug Discov | 2018 | 29977051 | PubTator, text mining | PubMed |
| CHP1 reduction ameliorates spinal muscular atrophy pathology by restoring calcineurin activity and endocytosis. | Brain | 2018 | 29961886 | PubTator, text mining | PubMed |
| Nusinersen in type 1 SMA infants, children and young adults: Preliminary results on motor function. | Neuromuscul Disord | 2018 | 29960818 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6607/papers?page=100